$6.720
+0.259 (+3.86%)收盤時
OCUL 資訊
OCUL 事件
Ocular Therapeutix Shares Drop 18.2% to $7.89
Ocular Therapeutix is down -18.2%, or -$1.76 to $7.89.
Ocular Therapeutix Shares Drop 22% to $7.53
Shares of Ocular Therapeutix (OCUL) are down 22% to $7.53 in morning trading after competitor 4D Molecular Therapeutics (FDMT) announced Phase 3 clinical data for its wet age-related macular degeneration drug candidate, 4D-150. Ocular Therapeutix is also developing a flagship wet AMD treatment, AXPAXLI, and preparing for its own FDA filing in Q4.
Ocular Therapeutix Shares Down 18.1% to $7.90
Ocular Therapeutix is down -18.1%, or -$1.75 to $7.90.
Ocular Therapeutix Completes Axpaxli NDA Pre-Meeting
Ocular Therapeutix announced the completion of its pre-new drug application, or NDA, meeting with the FDA for its investigational product candidate Axpaxli for the treatment of wet age-related macular degeneration. Based on the pre-NDA meeting, the company's expectations for the Axpaxli NDA package remain consistent with prior FDA communications, including the May Type C meeting. Ocular remains on track to submit the NDA in the fourth quarter of 2026.
Ocular Therapeutix Stock Price Rises
Ocular Therapeutix is up…
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。